-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on WAVE Life Sciences, Lowers Price Target to $12

Benzinga·07/31/2026 13:02:58
语音播报
Wedbush analyst Yun Zhong maintains WAVE Life Sciences (NASDAQ:WVE) with a Outperform and lowers the price target from $15 to $12.